HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NIBR-0213

a sphingosine-1-phosphate receptor type 1 antagonist; structure in first source

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - NIBR-0213: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - NIBR-0213: 3

Experts

1.	Angst, Daniela: 2 articles (01/2016 - 09/2012)
2.	Beerli, Christian: 2 articles (01/2016 - 09/2012)
3.	Bigaud, Marc: 2 articles (01/2016 - 09/2012)
4.	Bollbuck, Birgit: 2 articles (01/2016 - 09/2012)
5.	Bruns, Christian: 2 articles (01/2016 - 09/2012)
6.	Janser, Philipp: 2 articles (01/2016 - 09/2012)
7.	Quancard, Jean: 2 articles (01/2016 - 09/2012)
8.	Beckmann, Nicolau: 1 article (01/2016)
9.	Dawson, Janet: 1 article (01/2016)
10.	Dincer, Zuhal: 1 article (01/2016)

Related Diseases

1.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 09/21/2012 - "NIBR-0213 showed comparable therapeutic efficacy to fingolimod in experimental autoimmune encephalomyelitis (EAE), a model of human MS. These data provide convincing evidence that S1P(1) antagonists are effective in EAE. "
2.	Necrosis 01/01/2016 - "At the supra-maximal oral dose of 300 mg/kg QD, NIBR-0213 impaired lung function (with increased breathing rate and reduced tidal volume) within the first 24 hrs. Two weeks of NIBR-0213 oral dosing at 30, 100 and 300 mg/kg QD induced moderate pulmonary changes, characterized by alveolar wall thickening, macrophage accumulation, fibrosis, micro-hemorrhage, edema and necrosis. "
3.	Inflammation (Inflammations) 09/21/2012 - "The discovery of NIBR-0213, a competitive antagonist for S1P(1) that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue of Chemistry & Biology), suggests that fine-tuning of S1P(1) modulators may lead to novel immune modulators with better efficacy to adverse events ratio."
4.	Hemorrhage 01/01/2016 - "At the supra-maximal oral dose of 300 mg/kg QD, NIBR-0213 impaired lung function (with increased breathing rate and reduced tidal volume) within the first 24 hrs. Two weeks of NIBR-0213 oral dosing at 30, 100 and 300 mg/kg QD induced moderate pulmonary changes, characterized by alveolar wall thickening, macrophage accumulation, fibrosis, micro-hemorrhage, edema and necrosis. "
5.	Fibrosis (Cirrhosis) 01/01/2016 - "At the supra-maximal oral dose of 300 mg/kg QD, NIBR-0213 impaired lung function (with increased breathing rate and reduced tidal volume) within the first 24 hrs. Two weeks of NIBR-0213 oral dosing at 30, 100 and 300 mg/kg QD induced moderate pulmonary changes, characterized by alveolar wall thickening, macrophage accumulation, fibrosis, micro-hemorrhage, edema and necrosis. "

Related Drugs and Biologics

1.	Fingolimod Hydrochloride (FTY720)